Ami Lifesciences Pvt
Ami Lifesciences Pvt. is a prominent player in the pharmaceutical industry, headquartered in India. Established in 2003, the company has made significant strides in the development and manufacturing of high-quality active pharmaceutical ingredients (APIs) and intermediates. With a strong operational presence across various regions, Ami Lifesciences is dedicated to delivering innovative solutions that cater to the evolving needs of the global healthcare market. The company’s core offerings include a diverse range of APIs, particularly in the therapeutic areas of oncology, cardiology, and anti-infectives. Ami Lifesciences is recognised for its commitment to quality and compliance, ensuring that its products meet stringent international standards. With a robust market position, the company has achieved notable milestones, including successful collaborations and a growing portfolio that underscores its reputation as a trusted partner in the pharmaceutical sector.
DitchCarbon Score
How does Ami Lifesciences Pvt's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ami Lifesciences Pvt's score of 25 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ami Lifesciences Pvt's reported carbon emissions
In 2023, Ami Lifesciences Pvt. Ltd. reported total carbon emissions of approximately 5,327,000 kg CO2e for Scope 1, about 14,824,000 kg CO2e for Scope 2, and around 10,377,000 kg CO2e for Scope 3. This reflects a slight decrease in emissions from 2024, where Scope 1 emissions were about 5,291,000 kg CO2e, Scope 2 emissions were approximately 14,347,000 kg CO2e, and Scope 3 emissions were around 10,258,000 kg CO2e. Ami Lifesciences has set ambitious reduction targets to address its greenhouse gas emissions. The company aims to achieve a reduction of at least 4.5% in Scope 1 emissions, 9.0% in Scope 2 emissions, and 9.0% in Scope 3 emissions by 31st March 2028, using 2023 as the baseline year. Furthermore, Ami Lifesciences is committed to reaching net zero emissions across all scopes by 2050, with a strategy to be prepared and submitted by 31st December 2025. These commitments align with industry standards and reflect the company's proactive approach to mitigating climate change impacts within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 5,327,000 | 0,000,000 |
| Scope 2 | 14,824,000 | 00,000,000 |
| Scope 3 | 10,377,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ami Lifesciences Pvt is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
